PMID- 32848116
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 84
IP  - 10
DP  - 2020 Sep 25
TI  - Comparison of Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting 
      and Medical Therapy in Non-ST Elevation Acute Coronary Syndrome Patients With 
      3-Vessel Disease.
PG  - 1718-1727
LID - 10.1253/circj.CJ-20-0300 [doi]
AB  - BACKGROUND: The aim of this study is to compare the long-term prognosis of non-ST 
      elevation acute coronary syndrome (NSTE-ACS) patients with 3-vessel disease (3VD) 
      who underwent percutaneous coronary intervention (PCI), coronary artery bypass 
      grafting (CABG) or medical therapy (MT).Methods and Results:Overall, 3,928 
      NSTE-ACS patients with 3VD were consecutively enrolled from April 2004 to 
      February 2011 at Fu Wai Hospital. Patients were followed up for a median of 7.5 
      years, and were divided into PCI, CABG or MT groups according to their treatment. 
      Compared with patients undergoing PCI, CABG patients had lower rates of 
      myocardial infarction (MI), unplanned revascularization, major adverse 
      cardiovascular and cerebrovascular events (MACCE) and a higher rate of stroke 
      (all P<0.05). Compared with MT, PCI and CABG had lower incidences of all adverse 
      outcomes (all P<0.05), except for a similar rate of stroke between PCI and MT. 
      Kaplan-Meier analysis showed similar results. After adjusting for confounders, 
      CABG was independently associated with a lower risk of cardiac death, 
      revascularization and MACCE compared with PCI (all P<0.05). Compared with MT, PCI 
      reduced long-term risk of death, whereas CABG reduced long-term risk of death, 
      revascularization and MACCE events (all P<0.05). CONCLUSIONS: In NSTE-ACS 
      patients with 3VD, CABG is independently associated with a lower risk of 
      long-term cardiac death, revascularization and MACCE compared with PCI. Patients 
      who received MT alone had the highest risk of long-term MACCE.
FAU - Jia, Sida
AU  - Jia S
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Zhang, Ce
AU  - Zhang C
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Jiang, Lin
AU  - Jiang L
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Xu, Lianjun
AU  - Xu L
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Tian, Jian
AU  - Tian J
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Zhao, Xueyan
AU  - Zhao X
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Feng, Xinxing
AU  - Feng X
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Wang, Dong
AU  - Wang D
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Zhang, Yin
AU  - Zhang Y
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Sun, Kai
AU  - Sun K
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Xu, Jingjing
AU  - Xu J
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Liu, Ru
AU  - Liu R
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Xu, Bo
AU  - Xu B
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Hui, Rutai
AU  - Hui R
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Gao, Runlin
AU  - Gao R
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Gao, Zhan
AU  - Gao Z
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Yuan, Jinqing
AU  - Yuan J
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
FAU - Song, Lei
AU  - Song L
AD  - Fu Wai Hospital, National Center for Cardiovascular Diseases, Peking Union 
      Medical College & Chinese Academy of Medical Sciences.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20200826
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - Circ J. 2020 Sep 25;84(10):1686-1688. PMID: 32908074
MH  - Acute Coronary Syndrome/*complications/*drug therapy/surgery
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin Receptor Antagonists/*adverse effects
MH  - Angiotensin-Converting Enzyme Inhibitors/*adverse effects
MH  - Calcium Channel Blockers/*adverse effects
MH  - Coronary Artery Bypass/*adverse effects
MH  - Coronary Artery Disease/*complications/*drug therapy/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/chemically induced/mortality
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/chemically induced/mortality
MH  - Treatment Outcome
OTO - NOTNLM
OT  - 3-vessel coronary artery disease
OT  - Acute coronary syndrome
OT  - Coronary artery bypass grafting
OT  - Medical therapy
OT  - Percutaneous coronary intervention
EDAT- 2020/08/28 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - 10.1253/circj.CJ-20-0300 [doi]
PST - ppublish
SO  - Circ J. 2020 Sep 25;84(10):1718-1727. doi: 10.1253/circj.CJ-20-0300. Epub 2020 
      Aug 26.